SCHEMBL206343

SCHEMBL206343

[C]1=CN=Cc2ccccc2N1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL107508 0.70 GAA (0.36) GAAMAPT
SCHEMBL211612 0.65 GAA (0.36) GAAMAPT
SCHEMBL28185725 0.64 GAA (0.34) GAAMAPT
Hydrochloric Acid SCHEMBL2360762 0.64 GAA (0.34) GAAMAPT
Hydrochloric Acid SCHEMBL3772181 0.64 GAA (0.34) GAAMAPT
SCHEMBL29157769 0.64 GAA (0.34) GAAMAPT
SCHEMBL5604886 0.64 GAA (0.34) GAAMAPT
SCHEMBL28157348 0.64 GAA (0.34) GAAMAPT
SCHEMBL207759 0.64 GAA (0.44) GAAMAPT
Hydrochloric Acid SCHEMBL28292448 0.62 GAA (0.33) GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4337639-A1 NAMPT INHIBITORS AND USES THEREOF Remedy Plan, Inc. (US) 2024-03-20 EP claimed
WO-2022241257-A1 NAMPT INHBITORS AND USES THEREOF REMEDY PLAN, INC. (US) 2022-11-17 WO claimed
CN-111518122-A Boron-nitrogen hetero-aromatic ring compound and application thereof 南京知研科技有限公司 2020-08-11 CN claimed
EP-0552489-B1 Peptide, production and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1998-03-04 EP claimed
US-5614497-A TREATMENT OF HYPERTENSION, CARDIOVASCULAR DISEASE AND RENAL DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-03-25 US claimed
CN-1033453-C Pyridylthiazolidine carboxylic acid amide derivative and its preparing method SANKYO CO (JP) 1996-12-04 CN claimed
EP-0698015-A1 PREPARATION OF N-CYANODITHIOIMINO-CARBONATES AND 3-MERCAPTO-5-AMINO-1H-1,2,4-TRIAZOLE GENENTECH, INC. (US) 1996-02-28 EP claimed
US-5391772-A In presence of a dry aprotic solvent and proton acceptor MERCK & CO., INC. (US) 1995-02-21 US claimed
WO-1995001970-A1 ALCOHOL TO AZIDE SN2 CONVERSION MERCK & CO., INC. (US) 1995-01-19 WO claimed
EP-0552489-A2 Peptide, production and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-28 EP claimed
US-12042513-B2 Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-07-23 US disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 WO disclosed
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 US disclosed
US-20240226302-A1 BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-07-11 US disclosed
US-20240228671-A1 POLYPEPTIDYL LINKERS Quantum-Si Incorporated (US) 2024-07-11 US disclosed
US-5614497-A TREATMENT OF HYPERTENSION, CARDIOVASCULAR DISEASE AND RENAL DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-03-25 US disclosed
US-5462934-A Cholinesterase inhibitor; learning enhancement TAKEDA CHEMICAL INDUSTRIES (JP) 1995-10-31 US disclosed
US-5391772-A In presence of a dry aprotic solvent and proton acceptor MERCK & CO., INC. (US) 1995-02-21 US disclosed
EP-0560235-A1 Condensed heterocyclic ketone derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1993-09-15 EP disclosed
EP-0552489-A2 Peptide, production and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226302-A1 BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA CPT1B, IGF2BP2, IGF2BP3 GAA 704/4885MAPT 4157/4885
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF UACA, ADCYAP1R1, ADCY1 GAA 673/4885MAPT 506/4885
US-20240228671-A1 POLYPEPTIDYL LINKERS VIP, DNPEP, PREP GAA 109/4885MAPT 3367/4885
US-12042513-B2 Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof CRBN, PSMA6, PSMA3 GAA 276/4885MAPT 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.